Answers are grounded in this paper and cite their sources.
THE 30th EUROPEAN Hematology Association (EHA) Congress marked a pivotal year in advancing the treatment and understanding of myeloproliferative neoplasms (MPN). Breakthroughs in novel therapies, disease biology, and molecular risk stratification highlighted EHA 2025 Congress as a key event shaping the future of MPN care. Herein are the main takeaways from pivotal presentations.
No takes yet. Share an insight, caveat, or question.
Erika Morsia (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: